Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

We screened TP53 mutations in 168 MDS patients who were treated with HMA and evaluated predictive and prognostic value of TP53 mutations. Overall response to HMA was not different based on TP53 mutation status (45% vs. 32% in TP53-mutated and wild type [WT], respectively, P = 0.13). However, respons...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Takahashi, Koichi, Patel, Keyur, Bueso-Ramos, Carlos, Zhang, Jianhua, Gumbs, Curtis, Jabbour, Elias, Kadia, Tapan, Andreff, Michael, Konopleva, Marina, DiNardo, Courtney, Daver, Naval, Cortes, Jorge, Estrov, Zeev, Futreal, Andrew, Kantarjian, Hagop, Garcia-Manero, Guillermo
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924706/
https://ncbi.nlm.nih.gov/pubmed/26871476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7290
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы